The C677T Methylenetetrahydrofolate Reductase Polymorphism Influences the Homocysteine-Lowering Effect of Hormone Replacement Therapy
- 1 May 1999
- journal article
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 67 (1) , 43-48
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- A randomized controlled study of the effects of 17Beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal womenObstetrics & Gynecology, 1998
- A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarctionAtherosclerosis, 1997
- Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study.Journal of Clinical Investigation, 1996
- The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemiaQJM: An International Journal of Medicine, 1996
- Homocysteine and coronary atherosclerosisJACC, 1996
- Plasma homocysteine and menopausal status**European Journal of Clinical Investigation, 1995
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Hormone replacement therapy may reduce high serum homocysteine in postmenopausal womenEuropean Journal of Clinical Investigation, 1994
- Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidencePreventive Medicine, 1991
- Homocyst(e)inemia in daily practiceCoronary Artery Disease, 1990